IC
ARCT icon

Ikarian Capital’s Arcturus Therapeutics ARCT Stock Holding History

Ikarian Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-227,200
Closed -$4.19M – 181
2025
Q3 		$4.19M Buy
+227,200
New +$3.65M 0.42% 64
2025
Q2 		– Sell
-150,000
Closed -$1.59M – 139
2025
Q1 		$1.59M Buy
+150,000
New +$2.38M 0.2% 78

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital's ARCT Position: Q4 2025 in Review

Ikarian Capital sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 10,721 shares — an estimated $198K sold.

Ikarian Capital first reported a position in ARCT in Q4 2024 and held it in 4 quarters. The position peaked at $3.39M in Q4 2024. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Ikarian Capital reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 10,721 Arcturus Therapeutics shares in Q4 2025, an estimated $198K.
  • Ikarian Capital first reported a position in Arcturus Therapeutics in Q4 2024 and held it in 4 quarters.
  • Ikarian Capital's Arcturus Therapeutics position peaked at $3.39M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.